Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase
- 5 August 2010
- journal article
- Published by Oxford University Press (OUP) in Carcinogenesis: Integrative Cancer Research
- Vol. 31 (10), 1787-1793
- https://doi.org/10.1093/carcin/bgq158
Abstract
Sphingolipid metabolism is driven by inflammatory cytokines. These cascade of events include the activation of sphingosine kinase (SK), and subsequent production of the mitogenic and proinflammatory lipid sphingosine 1-phosphate (S1P). Overall, S1P is one of the crucial components in inflammation, making SK an excellent target for the development of new anti-inflammatory drugs. We have recently shown that SK inhibitors suppress colitis and hypothesize here that the novel SK inhibitor, ABC294640, prevents the development of colon cancer. In an azoxymethane (AOM)/dextran sulfate sodium (DSS) mouse model, there was a dose-dependent decrease in tumor incidence with SK inhibitor treatment. The tumor incidence (number of animals with tumors per group) in the vehicle, ABC294640 (20 mg/kg) and ABC294640 (50 mg/kg) groups were 80, 40 and 30%, respectively. Tumor multiplicity (number of tumors per animal) also decreased from 2.1 ± 0.23 tumors per animal in the AOM + DSS + vehicle group to 1.2 ± 0 tumors per animal in the AOM + DSS + ABC294640 (20 mg/kg) and to 0.8 ± 0.4 tumors per animal in the AOM + DSS + ABC294640 (50 mg/kg) group. Importantly, with ABC294640, there were no observed toxic side effects. To explore mechanisms, we isolated cells from the colon (CD45-, representing primarily colon epithelial cells) and (CD45+, representing primarily colon inflammatory cells) then measured known targets of SK that control cell survival. Results are consistent with the hypothesis that the inhibition of SK activity by our novel SK inhibitor modulates key pathways involved in cell survival and may be a viable treatment strategy for the chemoprevention colitis-driven colon cancer.Keywords
This publication has 39 references indexed in Scilit:
- Mesalamine Inhibits Epithelial β-Catenin Activation in Chronic Ulcerative ColitisGastroenterology, 2010
- A Novel Sphingosine Kinase Inhibitor Induces Autophagy in Tumor CellsThe Journal of pharmacology and experimental therapeutics, 2010
- Pharmacology and Antitumor Activity of ABC294640, a Selective Inhibitor of Sphingosine Kinase-2Journal of Pharmacology and Experimental Therapeutics, 2010
- Role for sphingosine kinase 1 in colon carcinogenesisThe FASEB Journal, 2008
- A role for sphingosine kinase 1 in dextran sulfate sodium‐induced colitisThe FASEB Journal, 2008
- Ginkgo biloba extract EGb 761 has anti-inflammatory properties and ameliorates colitis in mice by driving effector T cell apoptosisCarcinogenesis: Integrative Cancer Research, 2008
- Principles of bioactive lipid signalling: lessons from sphingolipidsNature Reviews Molecular Cell Biology, 2008
- Suppression of Ulcerative Colitis in Mice by Orally Available Inhibitors of Sphingosine KinaseDigestive Diseases and Sciences, 2007
- Chemically induced mouse models of intestinal inflammationNature Protocols, 2007
- Intracellular Role for Sphingosine Kinase 1 in Intestinal Adenoma Cell ProliferationMolecular and Cellular Biology, 2006